Home › Kanser sa Suso › South Dakota
Pag-aaral pangklinika para sa Kanser sa Suso sa South Dakota
20 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa South Dakota.
Mga Lungsod sa South Dakota
Opisyal na teksto ng pag-aaral (English)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Avera Cancer Institute, Sioux Falls
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06982521Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sanford USD Medical Center, Sioux Falls
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Avera Cancer Institute, Sioux Falls
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06324357A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Avera McKennan Hospital ( Site 0002), Sioux Falls
- Avera Cancer Institute - Yankton ( Site 0089), Yankton
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06966700Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Sanford Health, Sioux Falls
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sanford Cancer Center, Sioux Falls
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07174336A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Avera St. Mary's Hospital, Pierre
- Avera Cancer Institute, Sioux Falls
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06492616A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Sioux Falls
Nagre-recruitPhase 3
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07647328A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, SD, Pierre
- at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07405801Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Sanford - Sioux Falls, Sioux Falls
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- at 4 pa
Nagre-recruitPhase 3
Edad 18 hanggang 60 · Kababaihan · Na-update Set 2, 2026 · NCT05879926A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Research Site, Aberdeen
- Research Site, Pierre
Nagre-recruitPhase 3
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05774951E-Mindfulness Approaches for Living After Breast Cancer
- Rapid City Regional Hospital, Rapid City
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nagre-recruitPhase 3
Edad 18 hanggang 50 · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT06748222A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05377996Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Sanford Health, Sioux Falls
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 18, 2026 · NCT06757634I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Sanford Clinical Research, Sioux Falls
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT01042379Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT05142033Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Monument Health Rapid City Hospital, Rapid City
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Avera Cancer Institute, Sioux Falls
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT06401421Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.